Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation

Liver Transplantation

Volumn 22, Issue 5, 2016, Pages 635-643

  Crittenden, Neil E ^a   Buchanan, Laura A ^c   Pinkston, Christina M ^b   Cave, Barbra ^a,e   Barve, Ashutosh ^a,e,f   Marsano, Luis ^a,e,f   McClain, Craig James ^a,e,f   Jones, Christopher M ^a,e   Marvin, Michael R ^a,e   Davis, Eric G ^a,e   Kuns Adkins, Candice B ^c   Gedaly, Roberto ^c,d   Brock, Guy ^b   Shah, Malay B ^c,d   Rosenau, Jens ^c,d   Cave, Matthew C ^a,e,f  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e KentuckyOne Health   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHILD PUGH SCORE; COMBINATION DRUG THERAPY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; RETROSPECTIVE STUDY; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PATIENT SAFETY; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SAFETY; POLYMORPHISM, GENETIC; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84964700355     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24422     Document Type: Article

References (19)

1. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL,. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680-1686.
2. Gane EJ,. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (suppl 2): S36-S44.
3. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10 (pt 2): 1003-1019.
4. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-954.
5. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
6. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R,. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir plus sofosbuvir in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22-26, 2015; Vienna, Austria.
7. Kwo P, Gitlin N, Nahass R,. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir plus sofosbuvir in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. In: 50th Annual Meeting of the European Association for the Study of the Liver. April 22-26, 2015; Vienna, Austria.
8. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al., Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87: 1544-1553.
9. el Zayadi A, Khalil A, el Samny N, Hamza MR, Selim O,. Hepatic angiosarcoma among Egyptian farmers exposed to pesticides. Hepatogastroenterology 1986; 33: 148-150.
10. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al., Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
11. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, Peyton A,. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823-830.
12. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886.
13. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, et al., A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir plus sofosbuvir in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 In: EASL-The International Liver Congress 2015. Vienna, Austria; 2015.
14. Janssen Products, LP,. Prescribing Information OLYSIO (simeprevir) capsules, for oral use. 2015.
15. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al., Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
16. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al., An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.
17. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.,; for SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-659.
18. Gilead Sciences Inc. Prescribing Information Sovaldi (sofosbuvir) tablets, for oral use. 2015.
19. Abbvie Inc,. Prescrbing Information. VIEKIRA PAK (ombitasvir, paritaprevir, and rtonavir tablets; dasabuvir tablets), copackaged for oral use. 2015.